Clinical trials: Cancer Patient
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Carcinoma
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
This phase II trial studies the side effects of sunitinib malate and how well it works in treating patients with ovarian cancer that is persistent or has come back.
- Trial name
- NCT00979992
- Testing
- Laboratory Biomarker Analysis, Sunitinib Malate
- Where
- 97 sites in United States, South Korea
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Cervical Carcinoma
Pembrolizumab and Olaparib in Cervical Cancer Patients
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after…
- Trial name
- NCT04483544
- Testing
- pembrolizumab, olaparib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baptist Health South Florida
Breast Carcinoma
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat.
- Trial name
- NCT03220893
- Testing
- Digital Breast Tomosynthesis (DBT), Scintimammography
- Where
- 5 sites in United States
- Volunteers
- 3,023 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill).
- Trial name
- NCT00090363
- Testing
- ZD4054 15 mg, ZD4054 10 mg
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active.
- Trial name
- NCT01085214
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
This phase II trial is studying how well temsirolimus works in treating patients with recurrent or persistent cancer of the uterus.
- Trial name
- NCT01061606
- Testing
- temsirolimus
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Metastatic Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01993719
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
- Trial name
- NRR (NCT00182728)
- Testing
- surgery, therapy, radiation therapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ovarian Carcinoma
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal…
- Trial name
- NCT00853307
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoma
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with…
- Trial name
- NCT01909934
- Testing
- Brentuximab vedotin
- Where
- 40 sites in Belgium, Croatia and 8 more
- Volunteers
- 50 people
- Sponsor
- Takeda
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Melanoma, Stage IIIc Melanoma
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
- Trial name
- NCT01316692
- Testing
- laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Renal Cancer
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF).
- Trial name
- NCT00458536
- Testing
- Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Beth Israel Deaconess Medical Center
Neoplasms, Advanced Solid
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profile of trebananib (AMG 386) after intravenous administration in adult Japanese participants with advanced solid tumors.
- Trial name
- NCT02525536
- Testing
- Trebananib 3 mg/kg, Trebananib 10 mg/kg, Trebananib 30 mg/kg
- Volunteers
- 18 people
- Sponsor
- Takeda
Non-small Cell Lung Cancer
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Phase II trial to evaluate trametinib in patients with locally advanced non-squamous, non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with progressive disease on at least one prior line of…
- Trial name
- NCT03232892
- Testing
- Trametinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.